Sol-Gel Technologies (SLGL) Net Margin (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Net Margin of 3450.93% for Q1 2026, up 259661.0% year-over-year from N/an in Q1 2025, and up 138.79% quarter-over-quarter from 8895.83% in Q4 2025.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Net Margin (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Net Margin for 9 consecutive years, with 3450.93% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 259661.0% year-over-year to 3450.93%; the TTM figure through Mar 2026 stood at 349.18% (up 4666.0% YoY), while the FY2025 annual figure was 340.63%, up 19502.0% from the prior year.
- Net Margin advanced to 3450.93% in Q1 2026 per SLGL's latest filing, from 8895.83% in the prior quarter.
- Across five years, Net Margin topped out at 3450.93% in Q1 2026 and bottomed at 20103.96% in Q4 2024.
- Historically, Net Margin has averaged 2726.08% across 5 years, with a median of 0.0% in 2022.
- Annual changes were most pronounced in 2023 — Net Margin sank 1192819 bps — and 2025, when it soared 1120812 bps.
- Sol-Gel Technologies' Net Margin stood at 0.0% in 2022, then plunged by 2000000000 bps to 11928.19% in 2023, then slumped by 69 bps to 20103.96% in 2024, then soared by 56 bps to 8895.83% in 2025, then soared by 139 bps to 3450.93% in 2026.
- Business Quant data shows SLGL's Net Margin at 3450.93% in Q1 2026, 8895.83% in Q4 2025, and 1572.0% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | -785.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -785.62% |
| Mar 31, 2026 | 3,569.44% |
| Dec 31, 2025 | -490.09% |
| Sep 30, 2025 | -1,572.00% |
| Jun 30, 2025 | 62.86% |
| Mar 31, 2025 | 879.63% |
| Dec 31, 2024 | -2,193.88% |
| Sep 30, 2024 | -15.44% |
| Jun 30, 2024 | 23.41% |
| Mar 31, 2024 | 1,440.34% |
| Dec 31, 2023 | -1,209.62% |
| Sep 30, 2023 | -2,961.03% |
| Jun 30, 2023 | -1,192.59% |
| Mar 31, 2023 | 3,687.67% |
| Dec 31, 2022 | -6,205.00% |
| Sep 30, 2022 | -1,388.89% |
| Jun 30, 2022 | 3.81% |
| Mar 31, 2022 | 198,333.33% |
| Dec 31, 2021 | 67.08% |
| Sep 30, 2021 | 95.21% |